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Title: 
When no treatment is the best treatment: active surveillance strategies for low risk 
prostate cancers. 
 
Abstract: 
Although the incidence of prostate cancer is rising due to PSA screening and increased 
life expectancy, the metastatic potential of low-grade, organ-confined disease remains 
low. An increasing number of studies suggest that radical treatment in such cases 
confers little or no survival benefit at a significant cost to morbidity. Active surveillance 
is a promising management approach of such low-risk cancers: eligible patients are 
selected based on clinical and pathological findings at diagnosis and are regularly 
monitored with digital rectal examinations, PSA testing and biopsies. Treatment, 
however, is deferred until and unless there is evidence of disease progression. This is a 
key difference from watchful waiting, where treatment is avoided until and unless 
there are symptoms. The purpose of this work is to review the rationale and evidence 
behind active surveillance and to offer an overview of current active surveillance 
strategies and outcomes.  
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1. Introduction 
 
 Prostate cancer is the most common malignancy in men and the second most 
common malignancy in the Western world [1]. In the UK alone, more than 46,000 men 
are diagnosed and over 11,000 die from prostate cancer every year, according to 
Prostate Cancer UK [2].  
 The introduction of PSA in the 1990s drastically changed the landscape of 
prostate cancer diagnosis and management. PSA-related over-detection of prostate 
cancer and lead-time bias combined with all-cause mortality improvements now pose 
diagnostic and therapeutic dilemmas. Although low PSA values do not exclude the 
presence of high-grade disease and accurate assessment of risk requires the 
integration of multiple clinicopathological variables, the majority of patients are 
diagnosed as a result of PSA screening and harbor low-grade cancers [3] that have little 
to no metastatic potential [4]. In recent decades, this has resulted in a discrepancy 
between prostate cancer incidence and mortality rates. The value of radical 
prostatectomy and radiotherapy, previously the gold standard, is now increasingly 
questioned in the setting of low risk cancer as concerns regarding overdiagnosis and 
overtreatment continue to grow [5]. This is further complicated by the fact that the 
impact of PSA screening on overall cancer mortality remains unclear [6, 7].  
 Active surveillance (AS) has emerged as an alternative approach to tackle these 
conundrums. The key idea is the avoidance of treatment for low-grade-low risk cancers 
unless there is evidence of disease progression, thus limiting the exposure to radical 
treatment-related morbidity. However, this poses two important challenges: first, the 
accurate and early distinction of patients who have low-grade, low-risk cancers from 
those needing immediate treatment and, second, the accurate recognition of disease 
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progression such that radical treatment is delivered in a timely manner without 
compromising oncological outcomes [8]. These hurdles are not trivial and there are 
substantial efforts to address them in order to facilitate the clinical decision-making 
process. The concept of “clinically significant” cancer has been developed for this 
particular purpose and refers to tumours that, based on pre-defined clinicopathologic 
findings, have greater potential for progression and therefore require treatment. 
Therefore, a central objective in current AS research is identifying appropriate risk 
classifiers and optimizing their thresholds so as to minimize overtreatment. 
 
2. Clinically significant cancer 
 
 There is a lack of consensus amongst experts in defining “clinical significance” for 
men on active surveillance. Traditionally, most classification systems have used simple 
clinicopathological variables, including disease stage on digital rectal examination, 
tumour grade (Gleason score) or burden on standard biopsy and PSA-related metrics. 
Factors such as age, race and family history are often taken into account and the 
efficacy of new genomic classifiers is being investigated (although their prospective 
validation is incomplete). 
 The traditional Gleason grading system is based on a 5-point scale of histological 
features and is expressed as the sum of two scores, the first representing the dominant 
microscopic pattern and the second the next most frequent pattern. Cancer is deemed 
Gleason score 3, 4 or 5. The lowest score that can be currently assigned to cancer 
identified on prostate needle biopsy is 3+3=6. Although Gleason 6 cancer may harbor 
genetic aberrations such as PTEN inactivation and exhibits some invasive features [9], 
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it has negligible metastatic potential [4] and carries a very low risk of biochemical 
recurrence after radical treatment [10].  
 Some microscopic patterns previously considered Gleason 3 before 2005 are 
now classified as 4, resulting in a shift in grading with an increase in the proportion of 
Gleason 7 (3+4 or 4+3) cancers. Gleason 3+3 and 3+4 disease carry a 15-year prostate 
cancer specific mortality rate of 0.2% and 1.2% respectively following radical 
treatment [11], reinforcing the view that low-grade, organ confined prostate cancer 
represents a distinct disease category with good prognosis.  
 The favorable prognostic features of Gleason 3+3 and 3+4 cancers distinguish 
them from Gleason 4+3 disease, but their nomenclature can contribute to patient 
anxiety [12]. As a result, a new grouping system based on 7869 prostatectomy samples 
was proposed in 2013. This system defines 5 separate grade groups according to 
prognostic significance (1: Gleason < or = 6; 2: Gleason 3+4; 3: Gleason 4+3; 4: Gleason 
8 and 5: Gleason 9 or 10) [13]. It was validated by a multi-institutional study of 20,845 
men treated by radical prostatectomy and 5501 men treated by radiotherapy [14]. The 
5-year biochemical recurrence-free survival was 96%, 88%, 63%, 48% and 26% for 
grade groups 1-5 respectively, confirming the grading system’s prognostic value and 
justifying its rapid endorsement by experts and the World Health Organization. 
 Prostate cancer risk classification systems are currently based on integrating 
tumour grade with other clinical variables such as stage and PSA level. The D’Amico 
criteria differentiate between low-risk (stage T1c, T2a and PSA level < or =10 ng/mL 
and Gleason score < or =6), intermediate-risk (stage T2b or Gleason score of 7 or PSA 
level >10 and < or =20 ng/mL) and high-risk patients (stage T2c or PSA level >20 
ng/mL or Gleason score > or =8) and most classification systems adopt a variation of 
this scheme [15]. The National Cancer Comprehensive Network (NCCN) includes a 
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modification of the Epstein criteria (stage T1c or lower, PSA density <0.15 ng/mL, 
Gleason score 6 or less, 2 positive biopsy cores or less and 50% maximal cancer 
involvement in any biopsy core) in order to define very-low-risk disease [16].  
 Tumour volume has been traditionally considered an indicator of clinical 
significance [17] and it is postulated that the dominant or index lesion drives the 
natural history of the disease, with satellite lesions playing a secondary role [18]. The 
most widely used volume threshold for clinical significance is 0.5 mL. It is derived from 
a classical series of just 139 cystoprostatectomy specimens with incidental prostate 
cancer [19]. Using epidemiological data, the authors estimated the probability of 
having a diagnosis of prostate cancer during a man’s lifetime to be 8%. They then 
ranked the specimens by prostate cancer volume. The top 8% had volumes from 0.5-
6.1 mL. It was, therefore, extrapolated that a tumour volume of 0.5 mL was likely to 
represent clinically significant prostate cancer [19].  In another cystoprostatectomy 
series of 97 specimens, in men in the UK where PSA screening rates are low, the same 
methodology found a threshold of 1.09 mls, illustrating the arbitrary nature of this 
volume cut-off [20]. Recent work in screen-detected cancer supports the suitability of 
the 0.5 mL threshold value for any tumour stage or grade, but for Gleason 3+3, organ-
confined disease this value could be as high as 1.3 mL for the index lesion and 2.5 mL 
for the total tumour volume [21].  
 In conclusion, although thresholds for clinical significance can differ from one 
study to the next and depend on the clinical setting, the concept itself is a vital tool that 
enables clinicians to make the best possible treatment decisions based on the available 
clinicopathological evidence. The way clinical significance is defined is constantly 
under revision and it is well possible that more variables (e.g. imaging parameters) are 
incorporated in its definition in the near future.    
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3. Active surveillance and watchful waiting  
 
 It is important to distinguish between the two main conservative approaches in 
prostate cancer management, active surveillance and watchful waiting. Active 
surveillance applies to younger men with low-risk disease and a life expectancy of 
more than 10 years. Men are followed up according to a pre-defined schedule involving 
regular clinical examinations, PSA measurements, prostatic biopsies and imaging in an 
effort to detect progression early and, if necessary, to deliver treatment with curative 
intent. On the other hand, watchful waiting, usually reserved for patients with a life 
expectancy less than 10 years, refers to disease monitoring with the purpose of 
delivering palliative therapy if and when symptoms occur, so as to minimize 
treatment-related toxicity. This approach is tailored to a specific patient’s needs and, as 
such, there are no specific watchful waiting protocols.  
 There are three significant randomized controlled trials comparing radical 
prostatectomy with conservative approaches, based on different populations of men. 
The Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) randomized 695 
patients to radical prostatectomy versus watchful waiting with a median follow up 
time of 13.4 years [6]. The mean age was 65 years, the mean PSA value was 13 ng/mL 
and the majority of the participants had locally advanced disease, diagnosed on digital 
rectal examination and therefore palpable.  A reduction of 12.7 percentage points for 
cumulative incidence of death from any cause and 17.7 percentage points for prostate 
cancer-related cumulative incidence of death confirmed a substantial reduction in 
mortality after radical prostatectomy. In addition, it was concluded that prostatectomy 
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reduced the risk of metastatic disease and the need for androgen deprivation therapy 
[6].  
  In the Radical Prostatectomy Versus Observation for Localized Prostate Cancer 
(PIVOT), 731 men less than 75 years of age with localized prostate cancer (T1-
T2NxM0, any grade) were randomized to radical prostatectomy or observation with a 
median follow up of 10 years [22]. The absolute risk reduction in the intervention 
group was only 2.9 percentage points for all-cause mortality and 2.6 percentage points 
for prostate cancer-specific mortality. Nevertheless, RP was associated with reduced 
all-cause mortality among men with PSA>10 ng/mL and possibly intermediate-risk 
(stage T2b or Gleason score of 7 or PSA level between 10 and 20 ng/mL) or high-risk 
(stage T2c or Gleason score > or =8 or PSA level >20 ng/mL) disease, as designated by 
the D’Amico criteria. PIVOT has been criticized for its low statistical power and low 
adherence to treatment in the intervention group, but nevertheless indicated a 
negligible short-term effect of prostatectomy on mortality in older men with low risk 
disease. It would, therefore, appear reasonable to offer watchful waiting strategies to 
such men, especially if their life expectancy is low. In SPCG-4 only 12% of men had 
clinical stage T1c and the mean PSA value was relatively high (13 ng/mL), in contrast 
with the PIVOT trial where 50% of men had T1c and a lower mean PSA (7.8 ng/mL). It 
is, therefore, not surprising that the key finding of SPCG-4 (i.e. that radical 
prostatectomy benefits men with palpable, localized prostate cancer) is not directly 
comparable with the findings from PIVOT [23]. 
The UK Prostate Testing for Cancer and Treatment (ProtecT) randomized study 
compared active monitoring, radical prostatectomy and radical radiotherapy in 
patients with early, localized prostate cancer diagnosed after screening PSA was 
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offered via the general practitioner [24]. A total of 1643 patients were randomized to 
the three groups with a median age of 62 years and median PSA 4.6 ng/mL. The 
majority of the tumours were low–risk in terms of both grade (Gleason 6 in 77%) and 
stage (T1c in 76% of patients). The study concluded that death from prostate cancer as 
well as all-cause mortality in such men remained low at 10 years of follow up 
(approximately 1% and 10% respectively) regardless of the assigned treatment. 
Although the rates of clinical progression and metastatic disease were lower in the 
treatment groups compared to active monitoring (p<0.001 and p=0.004 respectively), 
it was not possible to conclude that immediate treatment translates into significant 
improvements in disease-specific or all-cause mortality. This, however, might be due to 
the fact that further follow-up is needed to demonstrate a difference. It should be noted 
that active monitoring in PROTECT was done by regular PSA tests and did not include 
MRI or planned repeat biopsies. The main trigger for clinical review in order to 
consider a change in clinical management was a PSA level increase of at least 50% in 
the previous 12 months. Subsequent possibilities included further monitoring, 
additional tests and radical or palliative treatment.  
 The ProtecT group also assessed urinary, bowel and sexual function as well as 
quality of life and general health of all men enrolled in the study, according to intention 
to treat [25]. Prostatectomy had the greatest negative effect on sexual function and 
continence at 6 months and continued to have the greatest effect at 6 years post 
treatment. In terms of continence, radical prostatectomy was associated with 46% pad 
use at 6 months, compared to 4% in the active monitoring group and 5% in the 
radiotherapy group. By 6 years, the rate of pad use in the radical prostatectomy group 
was 17%, compared to 8% in the active monitoring group and 4% in the radiotherapy 
group. Of the 545 men randomized to the active monitoring group, approximately 40% 
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had radical treatment at 6 years according to the latest report [24]. Sexual function was 
significantly affected across all groups with 67% of men reporting erections sufficient 
for intercourse at baseline, whilst at 6 months this percentage was 52% for those 
randomized to monitoring, 22% for those randomized to radiotherapy and 12% for 
those randomized to radical prostatectomy. Overall quality of life reflected function 
and there were no differences in anxiety, depression, and general or cancer-related 
health between the three groups.   
 In summary, SPCG-4 confirmed that the long-term mortality benefits of radical 
prostatectomy for palpable prostate cancer are largely seen in men younger than 65 
years. PIVOT highlighted that the absolute risk difference between surgery and 
observation is minimal in men with localized, low-risk prostate cancer and becomes 
larger in men with greater PSA values and higher risk disease. Finally, for PSA 
screening-detected, localized low-risk cancers, ProtecT reinforced the notion that 
surgery and radiotherapy have similar oncological outcomes with active surveillance at 
10 years of follow up, albeit at a significant cost on quality of life. Taken together, this 
evidence suggests that, although radical treatment is most likely beneficial for younger 
men with intermediate to high risk disease, active surveillance should be seriously 
considered for men with low-risk prostate cancers, the majority of which are now PSA-
detected. 
 
4. Active surveillance strategies 
 
 There are currently several AS programs worldwide with significant variation in 
their inclusion criteria. AS monitoring is based on serial clinical examinations, PSA 
measurements and prostate biopsies, with MRI being increasingly used. However, 
 11 
there are varying degrees of flexibility. Unsurprisingly, stringent monitoring and lower 
disease reclassification thresholds are associated with higher intervention rates [26]. 
The entry criteria and thresholds for intervention for some of the largest AS cohorts 
are summarized in Table 1 and their most recently published oncological outcomes in 
Table 2. It is important to take into account the entry criteria and monitoring protocol 
when interpreting oncological outcomes for any AS programme. 
 From the available evidence, it appears that AS has overall favorable oncologic 
outcomes while reducing the risk of treatment-related complications and maintaining 
quality of life. AS has, however, attracted criticism from those who see it as doing too 
little as well as those who see it as doing too much. Some authors have significant 
concerns about potentially missing the opportunity for cure if progression is 
undetected. In addition, there is anxiety about worse functional outcomes from radical 
treatments, either due to disease progression itself (which imposes the need for more 
complex therapeutic strategies) or the effect of having radical treatment at an older 
age. Others are concerned about the problems conferred by monitoring such as repeat 
biopsies and the psychological burden for patients who receive a diagnosis not 
immediately addressed with curative treatment. However, a recent systematic review 
of studies measuring health-related quality of life in 966 men on AS concluded that 
most patients report good quality of life and do not suffer any major negative 
psychological effects [27]. 
 
5. Disease reclassification 
 
 Although accurate classification at diagnosis is key, prompt detection of disease 
progression, sometimes referred to as reclassification, during active surveillance is 
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equally important. PSA elevation (despite limitations arising from its demonstrated 
lack of specificity), adverse biopsy features (volume or grade) and clinical upstaging 
are the most common triggers for intervention, although the use of magnetic resonance 
imaging and molecular biomarkers is gaining ground [28]. The prognostic value of each 
of these metrics is being evaluated and there is noticeable variation between different 
active surveillance cohorts in terms of the different thresholds used.   
 In a meta-analysis of the factors that trigger change to radical treatment 
including 7627 men from 26 surveillance cohorts with a median follow up of 3.5 years, 
8.8% of patients received radical treatment every year most commonly due to adverse 
biopsy findings, prostate specific antigen triggers and patient choice driven by anxiety 
[29]. Unsurprisingly, the rate of change to radical treatment was highest amongst men 
with higher baseline PSA or disease stage and in programs with scheduled repeat 
biopsies. 
 In a systematic review of 61 articles, the extent of cancer at biopsy (number of 
positive cores or percentage of core involvement) along with PSA density and 
percentage of free PSA were found to be useful for predicting disease progression [30]. 
Specifically, the authors reported that greater extent of cancer at initial biopsy as well 
as on confirmatory biopsies carry prognostic significance for progression. The 
evidence for the prognostic role of age, race and family history was found to be less 
robust, but these factors should also be considered. In another large meta-analysis of 
32 studies encompassing 24,236 patients on AS for early stage prostate cancer, PSA 
density, more than one positive core and race were significantly associated with 
histological progression [31]. Interestingly, age, PSA levels and suspicion on MRI were 
not. A recent retrospective study also showed that in 102 men on AS with a median 
follow up of 9.25 years, only PSA density above 0.15 was a significant predictor of 
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disease reclassification with a mean time to reclassification of 4.7 years (IQR 2.8-7.9) 
[32]. In this study, there was no significant difference in metastasis-free and overall 
survival between patients who received treatment and those that continued on AS 
despite reclassification. 
 Table 1 summarizes the intervention triggers for some of the largest AS cohorts. 
Generally, disease reclassification (as defined in each cohort) and patient preference 
play a major role. In the UCSF cohort, the median time to disease reclassification was 
17 months (IQR 10–33 months) and the median time to treatment was 25 months (IQR 
15–45). Almost 60% of patients underwent treatment (mostly radical prostatectomy) 
and their PSA recurrence-free survival at 1 year was 97%. PSA density was positively 
associated with biopsy reclassification.  In the Australian cohort, 38% of men received 
treatment, 88% of which was due to disease progression (mainly progression on 
biopsy). The median time to radical treatment was 90 months (IQR 63-146) and a high 
PSA density or abnormal DRE were the main predictors of significant cancer. In the 
Royal Marsden cohort, where the 5-year treatment-free probability was 70% (95% CI: 
65-75%), the rate of adverse histology at 5 years was 22% (95% CI: 16-29%) and was 
best predicted by a Gleason score of 3+4, a PSA velocity greater than 1 ng/ml per year 
and a low free/total PSA ratio. In the Johns Hopkins cohort, the cumulative incidence of 
curative intervention was 57% and this was mostly associated with PSA density and a 
greater number of positive cores. Although in the PRIAS cohort 73% of men had 
discontinued AS at 15 years due to reclassification, the authors pointed out that many 
had favorable histology after prostatectomy and concluded that only Gleason 
upgrading and T3 stage were reliable indicators for recommending a transition to 
radical treatment.  
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6. MRI in active surveillance 
 
 Multiparametric magnetic resonance imaging (mpMRI), which incorporates T2-
weighted, dynamic contrast-enhanced, and diffusion-weighted sequences, is being 
increasingly used in prostate cancer active surveillance. This technique allows the 
integration of anatomical, biological and functional information. Most studies using 
histopathology specimens as reference standards have shown that mpMRI 
outperforms conventional anatomical imaging alone for the detection of prostate 
cancer [33-36]. There is also evidence that unfavorable findings on mpMRI, especially 
low ADC values, are associated with adverse histological features [37, 38]. Currently, 
almost all MRI reporting schemes are structured and use a 5-point scale to quantify the 
likelihood that clinically significant prostate cancer is present within a radiological 
region of interest. The PIRADS score introduced in 2012 (and its recently revised 
PIRADS-2 version) is widely used. This system aims to formalize the scoring based on 
findings for each of the T2, DCE and diffusion-weighted images and a study has shown 
a sensitivity, specificity and negative predictive value ranging from 0.70-0.84, 0.68-
0.86 and 0.58-0.95, respectively [39]. Another simpler system is the 5-point Likert 
scale, where the radiologist gives an assessment of the likelihood of clinically 
significant disease for a given lesion or the whole prostate. Both systems perform well 
[40], but some studies suggest higher accuracy for the Likert scale approach [41]. 
There are also concerns regarding the complexity versus clinical utility trade-off in 
PIRADS-2 as opposed to the less prescriptive Likert scale, although the introduction of 
PIRADS-2 is recent and further work is needed in this area [42]. 
 In detecting clinically significant prostate cancer in the general diagnostic setting, 
mpMRI has reported accuracy of 44-87%, sensitivity of 58-97% and specificity of 23-
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87% [43]. These values depend heavily on the definition of clinically significant 
prostate cancer and the mpMRI scoring system or threshold used (i.e. the point on the 
scale considered positive). There is evidence that the combination of pre-biopsy MRI 
and MRI-targeted biopsy detects at least an equal number of clinically significant 
cancer as standard TRUS biopsy, but reduces the number of men biopsied by a third 
and the men diagnosed with clinically insignificant prostate cancer by 10% [44]. This 
evidence is further corroborated by the recent results of the PROMIS trial, a 
prospective study testing mpMRI and TRUS biopsy with respect to 5 mm template 
mapping biopsy, which is generally considered as the most accurate reference test. In 
573 men with elevated PSA (less than 15 ng/mL) who underwent all three tests, MRI 
outperformed TRUS in both detecting and ruling out clinically significant cancer, with a 
sensitivity of 93% (95% CI: 88-96) versus 48% (95% CI: 42-55) and a negative 
predictive value of 89% (95% CI: 83-94) versus 74% (95% CI: 69-78) [45]. Therefore, 
mpMRI could have a prominent place as a triage test by reducing the need for prostate 
biopsies without compromising the detection of clinically significant cancer.  
 The potential value of MRI for monitoring patients already on active surveillance 
should not be overlooked. Although experience in this area is limited, converging 
evidence from MRI-based AS cohorts suggests that serial imaging improves the 
prediction of pathological progression compared to clinicopathological variables alone, 
whereas stable MRI findings are associated with pathological stability [46, 47, 48].  A 
meta-analysis of MRI performance involving a total of 1028 surveillance patients 
demonstrated a low positive predictive value and sensitivity but a high negative 
predictive value and specificity, suggesting that although a negative MRI is reassuring, 
men with suspicious MRI lesions should be closely monitored [49].  
 In summary, mpMRI could be useful in AS through (i) identifying men who would 
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most benefit from additional biopsy (as presence of suspicious lesions on MRI predicts 
unfavorable histology [50]),  (ii) increasing the diagnostic accuracy of prostate biopsy 
(as MRI-targeted biopsies in MRI-positive men increase the detection of significant 
cancers [51], outperform standard biopsies [52, 53] and reduce misclassification [54]), 
(iii) reducing the number of biopsies needed to diagnose significant cancer [55] and 
the need for repeat biopsies [56] due to a high negative predictive value and (iv) 
monitoring diagnosed lesions. The European School of Oncology has recently 
published the PRECISE guidelines on MRI reporting in AS with the intention of 
developing a robust data set that will inform the threshold setting for clinical 
significance and significant change of MRI lesions in men with low and intermediate 
risk prostate cancer. The key recommendations are to report the size of any lesions in 
absolute values (diameter on an axial section and volume using 3 parameters or 
planimetry) at baseline and each subsequent MRI, together with an assessment of the 
likelihood of clinically significant change for all follow up MRIs on a Likert scale of 1-5 
[57].  
 
7. Biomarkers 
 
 A growing understanding of the molecular aspects of prostate cancer in recent 
years has led to the development of predictive or prognostic biomarker assays for the 
purpose of selecting and monitoring men on active surveillance. Although rigorous 
studies assessing the validity of these tests are still lacking, preliminary evidence is 
promising. Genomic tests could be particularly useful for identifying patients with a 
higher risk of oncological progression and cancer-specific mortality.  
 The Cell Cycle Progression Score (CCP) is based on measuring gene expression in 
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paraffin-embedded tumour samples through quantitative RT-PCR. It was first 
demonstrated to be a robust predictor of prostate cancer-related death in a cohort of 
patients that had radical prostatectomy or TURP [58]. It is important to note that this 
cohort was heterogeneous, including patients from different risk strata. The study 
findings, however, were subsequently extended to tissue obtained through needle 
biopsies in men managed conservatively [59]. In a similar study on prostatectomy and 
needle biopsy specimens, the Genomic Prostate Score (GPS) was derived by measuring 
the expression of genes associated with disease aggressiveness despite tumour 
heterogeneity or multifocality [60]. Although this study included some patients with 
intermediate risk Gleason 3+4 tumours (a group not meeting the eligibility criteria of 
certain AS programmes), GPS was a significant predictor of high-stage and high-grade 
disease.  
 Notable efforts to develop similar tests in urine include the PCA3 and TMPRSS2-
ERG assays. A study correlating urine PCA3 and TMPRSS2-ERG transcript levels, PSA 
density, genetic variants and androgenic status with outcome and pathological findings 
at biopsy found that urine biomarkers were associated with the presence of cancer 
[61].  Interestingly, PCA3 was also associated with the presence of Gleason 4 and the 
percentage of positive biopsy cores. It should be again emphasized that the validity of 
biomarkers should be further confirmed through their serial use in AS cohorts and a 
significant body of evidence justifying their widespread adoption is still lacking from 
the literature.   
 
8. Conclusion 
 
 Active surveillance is a promising management strategy for low and intermediate 
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risk prostate cancer. There are some ongoing dilemmas regarding its optimal 
implementation (e.g. whether flexible local protocols would be preferable to stringent 
international guidelines or whether academic units are a more suitable environment 
compared to community hospitals). Despite these and the heterogeneity amongst 
current AS cohorts that makes direct comparison of outcomes challenging, there is 
strong converging evidence that cancer-specific outcomes in the surveillance setting 
are comparable to those of radical treatments without the loss of function commonly 
associated with surgery or radiotherapy. Therefore, in the era of modern PSA 
screening, an active surveillance approach should be seriously considered for men with 
low-grade, low-volume disease. The key to success is appropriate selection of 
candidates based on clinical, pathological and radiological variables and the continuous 
assessment of reclassification risk during follow up. Multiparametric MRI appears to be 
a useful complementary tool for assessing risk and should be considered at baseline 
and during follow up. 
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Cohort Selection criteria Current monitoring protocol Criteria for intervention  
UCSF 
Welty et al. 2015 [62] 
PSA < 10 ng/mL 
T1 or T2 
Gleason 3+3 or less 
<33% positive cores 
<50% cancer involvement in any core 
PSA every 3 months 
TRUS every 6 months 
Annual 12-core sextant biopsy (confirmatory biopsy within 
12 months of diagnostic biopsy; then biopsies every 12-24 
months according to clinical risk) 
 
Biopsy reclassification; change in clinical stage; CAPRA 
risk reclassification; patient anxiety 
 
Australian  
Thompson et al. 2014 [63] 
PSA < 10 ng/mL 
Stage < T2b on DRE 
Gleason 3+3 
<20% positive cores  
<30% or 6 mm cancer in all positive cores 
 
PSA every 3 months for 3 years then 6-monthly 
DRE every 6 months for 3 years then annually 
Biopsies at 12 and 24-36 months, then every 3–5 years 
Watchful waiting once age >75 years or life expectancy <7 
years 
 
Adverse PSA kinetics (PSA doubling time <3 years or 
PSA velocity >0.75 ng/mL), DRE progression (clinical 
T stage ≥2b), biopsy upgrade (Gleason ≥ 7/ increasing 
proportion of grade 4), cancer volume progression 
(>20% of cores positive or >8 mm in any core) 
Royal Marsden  
Selvadurai et al. 2013 [64] 
 
T1 or T2  
PSA <15 ng/ml 
Gleason 3+3, but 3+4 permitted in patients >65 
PPC <50% of total number of biopsy cores 
 
DRE and serum PSA levels every 3 months in the first year, 
every 4 months in the second year and every 6 months 
thereafter 
TRUS biopsy after 18–24 months and then every 2 years  
 
PSAV >1 ng/ml per year, adverse histology on repeat 
biopsy (i.e. primary Gleason > or equal to 4+3, 
presence of cancer in >50% of cores) 
Sunnybrook (Toronto)  
Klotz L et al. 2015 [65] 
1995-1999: Gleason 3+3, PSA < 10 ng/mL (for 
patients older than 70: PSA < 15 ng/mL, Gleason 
score < or = to 3+4) 
 
January 2000: study restricted to low-risk 
(Gleason score 6 or less and PSA < 10 ng/mL) or 
favorable intermediate-risk disease (PSA 10-20 
ng/mL and/or Gleason score 3+4 or less)  
 
3-monthly PSA for 2 years, then 6-monthly 
Confirmatory biopsy within 12 months of initial biopsy, then 
every 3 to 4 years until age 80 
 
Short PSA doubling time (less than 3 years), histologic 
upgrade on repeat biopsy, clinical progression (i.e. 
development of a palpable nodule with histological 
confirmation) 
  
Johns Hopkins 
Tosoian et al. 2015 [66] 
 
T1c  
PSA density < 0.15 ng/mL  
Gleason 3+3 or less 
Two or fewer positive cores 
Maximum 50% involvement in any core  
 
DRE and PSA measurements (total and free) every 6 months 
Annual 12- to 14-core biopsy 
Gleason >6, >2 positive cores, >50% cancer 
involvement in any core 
PRIAS 
Bokhorst et al. 2016 [67] 
Before 2012: Gleason 3+3 or less, T2c stage or 
lower, PSA<10 ng/ml, two or fewer positive 
cores, PSA density <0.2 ng/ml/cm3 
 
2012-2015: criteria adapted to include minimal 
Gleason 3 + 4 and accommodate changes in 
number of positive cores obtained by MRI-
targeted or saturation biopsies 
3-monthly PSA and 6-monthly DRE for the first 2 years, 6-
monthly PSA and annual DRE thereafter 
Standard biopsies at 1, 4, 7, and 10 years after diagnosis, 
then every 5 years (yearly biopsies if PSA doubling time 0-10 
years) 
Bone scan if PSA >20 ng/ml 
Active treatment (recommended until end of 2014): 
Gleason > 3+3, more than 2 positive cores, stage > cT2, 
PSA doubling time 0-3 years 
 
Criteria adapted for Gleason 3+4 and >2 cores based 
on MRI or saturation biopsies 
 
Table 1: Summary of selection criteria, monitoring protocol and intervention or disease reclassification criteria for the largest recently published active surveillance cohorts. AS: Active Surveillance. DRE: 
Digital Rectal Examination. PSA: Prostate Specific Antigen. TRUS: Trans-Rectal Ultrasound. 
Revised tables 1 and 2
 Cohort n Median follow up Summary of oncological outcomes 
UCSF 
Welty et al. 2015 [62] 
810 
 
60 months 5-year overall survival: 98% 
5-year treatment-free survival: 60% 
5-year biopsy reclassification-free survival: 40% 
No prostate cancer deaths 
Australian  
Thompson et al. 2014 [63] 
650 55 months Prostate cancer-specific survival 100% 
Metastasis-free survival 100%  
Biochemical recurrence-free survival 99% 
Radical treatment-free survival at 5 and 10 years: 57% and 45 % respectively 
Median time to treatment 7.5 years 
 
Royal Marsden  
Selvadurai et al. 2013 [64] 
 
471 5.7 years 5-year rate of adverse histology 22% (95% CI: 16–29%)  
5-year treatment-free probability 70% (95% CI: 65–75%) 
2 deaths from prostate cancer 
 
Sunnybrook (Toronto)  
Klotz L et al. 2015 [65] 
819 6.4 years 10- and 15-year cause-specific survival rate 98.1% and 94.3% respectively 
Patients untreated at 5, 10, and 15 years: 75.7%, 63.5%, and 55.0% respectively  
149/993 (15%) patients died, 15 deaths (1.5%) from prostate cancer, 13 patients (1.3%) diagnosed with metastatic disease  
Cumulative hazard mortality ratio (other causes/prostate cancer): 9.2:1 
 
Johns Hopkins 
Tosoian et al. 2015 [66] 
 
1298 5 years Overall survival: 93% at 10 years, 69% at 15 years 
Cancer-specific survival: 99.9% at 10 years, 99.9% at 15 years 
Metastasis-free survival: 99.4% at 10 years, 99.4% at 15 years 
Grade reclassification (cumulative incidence): 26% at 10 years, 31% at 15 years 
Curative intervention (cumulative incidence): 50% at 10 years, 57% at 15 years 
 
PRIAS 
Bokhorst et al. 2016 [67] 
5302  10 years AS discontinuation (due to protocol-based re-stratification) at 5 and 10 years: 52% and 73% respectively 
Biopsy reclassification rate (Gleason >3+3 or >2 positive cores on any repeat biopsy): 22-33% 
1/3 patients undergoing RP had favorable pathologic features on histology (Gleason 3+3, pT2) 
 
 
Table 2: Summary of oncological outcomes for the largest recently published active surveillance cohorts. AS: Active Surveillance. PSA: Prostate Specific Antigen.  
 
